By: Elisa (EJ) Sobo
The US cannabis landscape is shifting quickly, and so is the way we talk about the plant and its uses. The push to end its prohibition has entailed a proliferation of stakeholder groups, each with its own labeling preferences. Interviews with Southern Californian parents using marijuana medically for children with intractable epilepsy (pharmaceutically uncontrolled seizures) taught me that what’s in a name matters—a lot. How it matters differs depending on who is talking, and what he or he seeks to accomplish when it comes to this plant and its products.
Cannabis—marijuana—has many medical applications, including for epilepsy. Parent interest in this rose sharply when CNN profiled its success with a child in Denver. However, little scientific research has been done with the plant (its legal classification makes that tricky), so doctors generally will not assist parents proactively in regard to its use. Word of mouth, online resources, and purveyor promises are often all that parents have to go by as they work out dosage and other aspects of their child’s cannabis regimen. My research explores how they manage this, which has implications for our understanding of how regular citizens contribute to biomedicine’s knowledge base and therapeutic tool kit. Findings also may be used to help improve service provision for these vulnerable families. Continue reading